|
MediGene's business operations concentrate on clinical research and development of cancer drugs with emphasis on liposome technology. For the time being, the focus is on
the cancer drug EndoTAG™-1. To continue the development of this drug candidate, MediGene aims to enter into a development and marketing partnership. MediGene already has two
drugs on the market: Eligard® for the treatment of prostate cancer, and Veregen® for the treatment of genital warts. Both drugs are successfully marketed
by partners. MediGene is preparing to out-licence the drug candidate RhuDex® for the treatment of rheumatoid arthritis.
With the help of our business development team we have found strong partners to further push on our research and development projects, and to expand the distribution of
our marketed drugs.
|
Marketed Drugs
Eligard®
Marketing partnership with Astellas Pharma
In January 2004, MediGene closed an agreement with the pharmaceutical company Astellas Pharma (previously Yamanouchi) for the commercialization of Eligard® in Europe.
Astellas Pharma, one of the three top leaders in the European urology field of medicine, became MediGene's sales partner for its first drug. This cooperation forms an ideal basis in order
to exploit the full economic potential of Eligard®.
Veregen®
Partnerships for Veregen®
In January 2006, MediGene concluded a partnership with Nycomed, Inc (previously Bradley Pharmaceuticals, Inc.) for the commercialization of Veregen® in the
USA. Nycomed is a US specialty pharmaceutcials company with a focus on dermatology. The agreement includes the commercialization of Veregen® on the US market, as well as an
extensive development cooperation to add further indications to the field of application of the ointment. Several partnerships for the commercialization of the drug have already been
concluded between MediGene and renowned companies in Europe and Asia. MediGene is planning to close further agreements in the near future.
|
Country
|
Partner
|
Market Approval
|
Marketing start
|
| North America |
|
|
|
| USA |
Nycomed Inc. |
granted |
February 2009 |
| Europe |
|
|
|
| Germany |
Abbott Arzneimittel
GmbH (previously Solvay) |
granted |
March 2010 |
| Austria |
Abbott Arzneimittel
GmbH (previously Solvay) |
granted |
|
| Switzerland |
Abbott Arzneimittel
GmbH (previously Solvay) |
|
|
| Spain |
Juste S.A.Q.F. |
|
|
| Portugal |
Juste S.A.Q.F. |
|
|
| Greece |
Meditrina Ltd. |
|
|
| Cyprus |
Meditrina Ltd. |
|
|
| Asia |
|
|
|
| Israel |
Teva Pharmaceutical
Industries |
|
|
| China |
GC Rise |
|
|
| South Corea |
JS Bio Pharm |
|
|
In case you have any questions regarding marketing partnerships for our marketed products, please contact
Ms. Michaela Fabry, Business Development:
email: m.fabry@medigene.com
phone: +49-89-8565-2956
|
Drug Candidates
Partnerships for our technologies and drug candidates
EndoTAG™-1
On the basis of its technology, MediGene is developing the drug candidate EndoTAG™-1. This product achieved excellent results in two phase II clinical trials in
pancreatic cancer and triple negative breast cancer indications. MediGene is currently searching for partners in order to conduct the phase III clinical trial in pancreatic
cancer of this promising candidate. It is an element of our corporate strategy to advance our projects in an ideal way, by means of partnerships for development and
commercialization.
RhuDex®
A successful phase Ila pilot trial of our drug candidate RhuDex® for the treatment of rheumatiod arthritis was already conducted.
Cooperation with scientific institutions
In order to support the development of our research projects, we built up an international scientific network through partnerships. Academic and clinical contacts and
cooperations have been established with more than 30 leading hospitals and institutions in Europe and in North America, such as the Children's Hospital Boston, the Sloan Kettering
Institute, the German Cancer Research Center, the Gene Center of the University of Munich, and the University of Chicago.
In case of any questions regarding licensing, please contact Ms. Sandra von Meier, Business Development
email: business.development@medigene.com
phone: +49-89-8565-2956
|
